GSK Stock Crumbles As Blenrep Comeback Falls Unexpectedly Short

October 24, 2025

•

1 min read

•

Investor's Business Daily

GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.

GSK (GSK) stock crumbled Friday after the Food and Drug Administration granted its blood cancer treatment, Blenrep, a narrower-than-expected approval. The agency signed off on several combinations using Blenrep to treat multiple myeloma patients who'... [2123 chars]

Read Original Article

Source: Investor's Business Daily

Visit Source

Share this article

Twitter Facebook

Back to business news